Perseus SENOLYTIX

MitoXcel™ Oncopeptides for Cancer

Perseus SENOLYTIX™ is an affiliated of SENOTHERAPEUTIX™

Perseus SENOLYTIX is developing novel MitoXcel oncopeptides to target cancer via this novel mechanism.  In pre-clinical studies, our MitoXcel geropeptides and oncopeptides have been administered at escalating doses for over 16 weeks with no evidence of toxicity, opening the door for a potential safe and effective new class of cancer therapeutics.